The Oxindole GW-5074 Inhibits JC Polyomavirus Infection and Spread by Antagonizing the MAPK-ERK Signaling Pathway.
GW-5074
JC polyomavirus
PML
cell signalling
experimental therapeutics
nephropathy
oxindole
polyomavirus
Journal
mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231
Informations de publication
Date de publication:
25 04 2023
25 04 2023
Historique:
medline:
27
4
2023
pubmed:
15
2
2023
entrez:
14
2
2023
Statut:
ppublish
Résumé
JC polyomavirus (JCPyV) is a ubiquitous, double-stranded DNA virus that causes the fatal demyelinating disease progressive multifocal leukoencephalopathy (PML) in immunocompromised patients. Current treatments for PML are limited to immune reconstitution, and no effective antivirals exist. In this report, we show that the oxindole GW-5074 (3-(3,5-dibromo-4-hydroxybenzylidene)-5-iodoindolin-2-one) reduces JCPyV infection in primary and immortalized cells. This compound potently inhibits virus spread, which suggests that it could control infection in PML patients. We demonstrate that GW-5074 inhibits endogenous ERK phosphorylation, and that JCPyV infection in GW-5074-treated cells cannot be rescued with ERK agonists, which indicates that the antiviral mechanism may involve its antagonistic effects on MAPK-ERK signaling. Importantly, GW-5074 exceeds thresholds of common pharmacological parameters that identify promising compounds for further development. This MAPK-ERK antagonist warrants further investigation as a potential treatment for PML.
Identifiants
pubmed: 36786589
doi: 10.1128/mbio.03583-22
pmc: PMC10127638
doi:
Substances chimiques
5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone
P0LE4QW0S6
Oxindoles
0
Antiviral Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0358322Subventions
Organisme : NINDS NIH HHS
ID : R35 NS116836
Pays : United States
Références
Neurotherapeutics. 2017 Oct;14(4):961-973
pubmed: 28913726
Degener Neurol Neuromuscul Dis. 2019 Dec 02;9:109-121
pubmed: 31819703
Bioorg Med Chem Lett. 2000 Feb 7;10(3):223-6
pubmed: 10698440
Front Microbiol. 2019 Apr 17;10:783
pubmed: 31065251
J Neurovirol. 1997 Oct;3(5):322-30
pubmed: 9372453
J Virol. 2018 Mar 14;92(7):
pubmed: 29321332
Methods Mol Biol. 2001;165:9-17
pubmed: 11217398
Indian J Urol. 2010 Apr;26(2):159-66
pubmed: 20877590
Curr Opin Virol. 2021 Apr;47:95-105
pubmed: 33690104
J Biol Chem. 2004 Jun 25;279(26):27735-42
pubmed: 15069063
Virology. 1989 Jun;170(2):353-61
pubmed: 2543122
J Investig Med High Impact Case Rep. 2017 Sep 27;5(3):2324709617734248
pubmed: 28989935
Trends Biochem Sci. 2011 Jun;36(6):320-8
pubmed: 21531565
Int J Mol Sci. 2019 Jul 12;20(14):
pubmed: 31336840
PLoS Pathog. 2009 Mar;5(3):e1000363
pubmed: 19325891
Curr Opin Cell Biol. 2019 Jun;58:50-60
pubmed: 30826604
J Infect Dis. 2009 Mar 15;199(6):837-46
pubmed: 19434930
Biochem Soc Trans. 2021 Feb 26;49(1):281-295
pubmed: 33439253
Neurology. 2018 May 15;90(20):e1815-e1821
pubmed: 29669908
J Virol. 2004 Jan;78(1):250-6
pubmed: 14671106
Clin Infect Dis. 2001 Jul 15;33(2):191-202
pubmed: 11418879
Annu Rev Virol. 2017 Sep 29;4(1):349-367
pubmed: 28637388
Int J Mol Sci. 2019 Sep 26;20(19):
pubmed: 31561471
J Natl Cancer Inst. 2011 Dec 7;103(23):1799-806
pubmed: 22021664
Biol Chem. 2017 Jul 26;398(8):839-855
pubmed: 28493815
Cells. 2019 Mar 24;8(3):
pubmed: 30909636
Am J Epidemiol. 2016 Jan 1;183(1):61-9
pubmed: 26667254
Front Immunol. 2021 Mar 25;12:614715
pubmed: 33841397
Nature. 1993 Jul 15;364(6434):249-52
pubmed: 8321321
Nat Rev Nephrol. 2012 Apr 17;8(7):390-402
pubmed: 22508181
Viruses. 2020 Sep 01;12(9):
pubmed: 32882975
Cells. 2021 Nov 18;10(11):
pubmed: 34831441
J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):885-9
pubmed: 26917698
Rev Med Virol. 2021 Nov;31(6):e2220
pubmed: 33729628
Neurology. 2009 Apr 28;72(17):1458-64
pubmed: 19129505